Explore

Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
Agenus to Release Q1 2026 Financial Results and Corporate Update

Agenus to Release Q1 2026 Financial Results and Corporate Update

Agenus to Release Q1 2026 Financial Results and Corporate Update
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Erasca Shares Plummet Amid Patient Death and Patent Dispute

Erasca Shares Plummet Amid Patient Death and Patent Dispute

Erasca Shares Plummet Amid Patient Death and Patent Dispute
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Trendline Trendline
Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences
Trendline Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline
Trendline Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Act Before Class Action Deadline